To conclude, in AML patients treated with standard dose 3 + 7 cytarabine and daunorubicin regimen, MDR1 and MRP2 gene expression in bone marrow and peripheral blood samples have no association with remission, resistance or relapse, nor with 1-year DFS or OS. This evidence concerns the gene ABCC2 and acute myeloid leukemia.